These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17645582)

  • 1. Introduction: Symposium on diabetes, inflammation and cardiovascular disease.
    Smith U
    J Intern Med; 2007 Aug; 262(2):142-4. PubMed ID: 17645582
    [No Abstract]   [Full Text] [Related]  

  • 2. [Timely intervention with insulin sensitizer. Controlling cardiovascular risks].
    MMW Fortschr Med; 2003 Jun; 145(23):56-7. PubMed ID: 12854228
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of diabetes in cardiovascular patients: diabetic heart disease.
    Peter R; Cox A; Evans M
    Heart; 2008 Mar; 94(3):369-75. PubMed ID: 18276822
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes mellitus. Proceedings of a symposium. November 6-8, 2002, New York, New York, USA.
    Am J Med; 2003 Dec; 115 Suppl 8A():1S-120S. PubMed ID: 14678858
    [No Abstract]   [Full Text] [Related]  

  • 6. [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
    MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603688
    [No Abstract]   [Full Text] [Related]  

  • 7. Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point?
    Goodarzi MO; Psaty BM
    JAMA; 2008 Nov; 300(17):2051-3. PubMed ID: 18984894
    [No Abstract]   [Full Text] [Related]  

  • 8. Glucose control in diabetes: which target level to aim for?
    Laakso M; Cederberg H
    J Intern Med; 2012 Jul; 272(1):1-12. PubMed ID: 22321169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 2 diabetes mellitus: prevention of macrovascular complications.
    Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intensive glucose control in type 2 diabetes is beneficial].
    Nilsson PM; Attvall S
    Lakartidningen; 2009 Sep 2-8; 106(36):2198. PubMed ID: 19817174
    [No Abstract]   [Full Text] [Related]  

  • 11. Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
    Lebovitz HE
    J Indian Med Assoc; 2008 Nov; 106(11):724-6. PubMed ID: 19368098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [How does the PROactive Study change therapy of diabetes?].
    Erdmann E
    MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
    [No Abstract]   [Full Text] [Related]  

  • 13. [Infarct prevention for diabetics. To lower blood sugar is not enough].
    MMW Fortschr Med; 2001 Nov; 143(46):61. PubMed ID: 11759608
    [No Abstract]   [Full Text] [Related]  

  • 14. Manipulating the vascular biology of coronary atherosclerosis in diabetes: new opportunities.
    Orford JL; Kinlay S; Fernandes J; Behrendt D; Ganz P; Selwyn AP
    J Lab Clin Med; 2001 Feb; 137(2):82-92. PubMed ID: 11174464
    [No Abstract]   [Full Text] [Related]  

  • 15. Vascular reactivity in diabetes mellitus.
    Dandona P
    Endocrinol Nutr; 2009 Dec; 56 Suppl 4():12-4. PubMed ID: 20629223
    [No Abstract]   [Full Text] [Related]  

  • 16. [Management of blood glucose--target of the management and its practice].
    Ishibashi S
    Nihon Rinsho; 2006 Nov; 64(11):2089-94. PubMed ID: 17087301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.
    Aryangat AV; Gerich JE
    Vasc Health Risk Manag; 2010 Mar; 6():145-55. PubMed ID: 20448799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
    Mazzone T
    Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.